IRMD Stock Recent News
IRMD LATEST HEADLINES
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRadimed Corporation (NASDAQ:IRMD ) Q1 2023 Earnings Conference Call May 4, 2023 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Scott Henry - ROTH Capital Operator Welcome to IRadimed Corporation First Quarter of the 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
IRadimed (IRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.
WINTER SPRINGS, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 first quarter financial results before the market opens on Thursday, May 4th. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ratio.
WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, President and Chief Executive Officer of the Company, will be presenting at the 35th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Monday, March 13, at 11:30 am PT.
IRadimed came in with a strong set of Q4 and full-year numbers. We noted tremendous momentum on IRMD's profitability front, with strong incremental ROIC on small reinvestment for growth.
Revenues rose 25.2% YOY to $14.9 million, due to a rapid acceleration of Patient Monitors and Disposables sales, and a significant contribution from a new product launch. IRMD announced a special cash dividend of $1.05 per share, which is payable to shareholders of record at the close of business on February 13th, 2023.